반응식
[C:1]([C:3]1[C:8]([NH:9][C:10]2[O:14][N:13]=[C:12]([C:15]3[CH:20]=[CH:19][CH:18]=[CH:17][CH:16]=3)[CH:11]=2)=[CH:7][C:6]([NH:21][C@H:22]([CH2:26][CH:27]2[CH2:29][CH2:28]2)[C:23]([NH2:25])=[O:24])=[C:5]([F:30])[CH:4]=1)#[N:2].[OH-].[Na+].OO.CC(O)=[O:37]>CCO.CS(C)=O>[NH2:25][C:23](=[O:24])[C@H:22]([NH:21][C:6]1[C:5]([F:30])=[CH:4][C:3]([C:1]([NH2:2])=[O:37])=[C:8]([NH:9][C:10]2[O:14][N:13]=[C:12]([C:15]3[CH:20]=[CH:19][CH:18]=[CH:17][CH:16]=3)[CH:11]=2)[CH:7]=1)[CH2:26][CH:27]1[CH2:28][CH2:29]1참가 물질
7
반응물 4
생성물 1
시약·촉매·용매 2
실험 절차
To a solution of (R)-2-(4-cyano-2-fluoro-5-(3-phenylisoxazol-5-ylamino)phenylamino)-3-cyclopropylpropanamide (75 mg) in EtOH (1 mL) and DMSO (0.5 mL) at room temperature, aq. 1N NaOH (0.5 mL) and aq. H2O2 (50%, 0.5 mL) were added. The mixture was stirred at room temperature for 15 min. HOAc (0.5 mL) was added. After being concentrated in vacuo, the residue was purified by HPLC to give the titled compound (13 mg). MS 424.4 (M+H); UV 201.0, 244.9, 289.1 nm; t 0.668 min.
후처리
- concentrationAfter being concentrated in vacuo
- customthe residue was purified by HPLC
출처 및 근거
- ORD 기록
- ord-003f5281502e465c86769a8053c35f8f
- 출처 데이터셋
- uspto-grants-2016_06
- 특허 번호
- US09359375B2
연결된 노트
불러오는 중…